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We investigated extramedullary disease in newly diagnosed mul-tiple myeloma patients and its impact on outcome followingfirst-line autologous stem cell transplantation. We identified
3744 adult myeloma patients who received up-front single (n=3391) or
tandem transplantation (n=353) between 2005 and 2014 with available
data on extramedullary involvement at diagnosis. The overall incidence
of extramedullary disease was 18.2% (n=682) and increased per year
from 6.5% (2005) to 23.7% (2014). Paraskeletal involvement was found
in 543 (14.5%) and extramedullary organ involvement in 139 (3.7%).
More patients with extramedullary organ involvement had multiple
involved sites (≥2; P<0.001). In a comparison of patients with single sites
with patients without the disease, up-front transplantation resulted in at
least similar 3-year progression-free survival (paraskeletal: P=0.86, and
extramedullary organ: P=0.88). In single paraskeletal involvement, this
translated less clearly into worse 3-year overall survival (P=0.07) while
single organ involvement was significantly worse (P=0.001). Multiple
organ sites were associated with worse outcome (P<0.001 and P=0.01).
First-line treatment with tandem compared with single transplantation
resulted in similar survival in patients with extramedullary disease at
diagnosis (P=0.13 for both). 
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ABSTRACT
Introduction
Multiple myeloma (MM) accounts for approximately 2% of all new cancer cases
and 13% of hematologic cancers with an age-adjusted incidence of 6 per 100,000
per year in the USA and Europe.1 Autologous stem cell transplantation (ASCT) and
the development of new agents have considerably increased the median survival of
MM patients.2 The disease is characterized by a clonal proliferation of malignant
plasma cells with a strong dependence on the bone marrow (BM) microenviron-
ment.3
However, in some MM patients, myeloma cells escape
the BM, resulting in extramedullary disease (EMD),
which can be further characterized by two different types
of involvement: 1) paraskeletal (PS), consisting of masses
that arose from bone lesions; and 2) extramedullary organ
involvement (EM), resulting from hematogenous spread
into different organs, skin and lymph nodes.4,5 At the time
of MM diagnosis, the incidence of EM involvement in
observational studies ranges from 1.7% to 4.5 using a
baseline staging that includes whole-body magnetic reso-
nance imaging (MRI) or positron emission tomography-
computed tomography (PET-CT).6 Paraskeletal involve-
ment is more frequent and varies from 7% to 34.2% due
to different definitions and access of sensitive imaging
techniques.7-10 Rates are also considered to be higher at
relapse or after surgery.11,12 Several studies reported that
EMD was associated with shorter survival rates, and thus
considered EMD as a high-risk feature. However, the evi-
dence of the effect of EMD at diagnosis is limited due to
small populations, heterogenous patient or intervention
selection, and relapse settings.13-16 Therefore, very limited
data are available to assess the role of EMD at diagnosis
of MM patients after up-front ASCT. This lack of evi-
dence is striking, since ASCT is standard therapy in first-
line therapy in eligible patients.17,18
Therefore, the objective of this study was to determine
the demographic and clinical characteristics of EMD in
MM patients at diagnosis and to evaluate its impact on
outcome after up-front ASCT as first-line therapy. For
this purpose, we analyzed 3744 patients with or without
EMD at diagnosis after up-front single or tandem ASCT
who had been reported to the European Society for Blood
and Marrow Transplantation (EBMT) registry between
2005 and 2014.
Methods
Study design and data collection 
We included adult patients with MM who had available data
on extramedullary involvement at time of diagnosis who
received an up-front single ASCT within 12 months of diagnosis
or a tandem ASCT within six months from first ASCT as first-
line therapy and who had been reported to the EBMT registry
between January 2005 and December 2014. Patients were con-
sidered eligible for analysis if there were full data available on
extramedullary involvement (yes or no) at time of diagnosis, its
location, and the number of sites. This study was performed in
accordance with the principles of the Declaration of Helsinki
and was approved by the Chronic Malignancies Working Party
of the EBMT. The EBMT is a non-profit, scientific society repre-
senting more than 600 transplant centers, mainly in Europe.
Data are entered, managed, and maintained in a central database
with internet access. Audits are routinely performed to deter-
mine the accuracy of the data. Data on extramedullary involve-
ment were extracted from the database using Med-B forms.
Patients whose transplant data are reported provided informed
consent to use the information for research purposes and data
are anonymized.
Definitions and statistical analysis
The primary end point was 3-year progression-free survival
(PFS), which was defined as the time from ASCT to disease pro-
gression or death from any cause. The secondary end points
were 3-year overall survival (OS), non-relapse mortality (NRM)
and response. Overall survival was defined as the time from
ASCT to death from any cause or last follow up. Non-relapse
mortality was defined as death without evidence of relapse or
progression, with relapse or progression as competing events.
Remission, progression and relapse were defined according to
standard EBMT criteria.19 
On the basis of type of extramedullary involvement, we
defined three groups of myeloma patients: 1) without EMD
(MM group); 2) with paraskeletal (PS group); and 3)
extramedullary organ involvement (EM group). In addition, we
determined and analyzed the impact of the number of involved
sites as one or multiple (≥ 2) sites. Disease stage at diagnosis was
determined according to the International Staging System (ISS; I-
III),20 Salmon and Durie stages I, II or III, and also according to
renal function A or B.21 Performance status at ASCT was
assessed with the Karnofsky score (≤80 indicating poor and >80
good status).22 Categorical variables were compared with the use
of the Fisher’s exact test or the χ² test. Continuous variables
were analyzed using the Kruskal-Wallis test for independent
samples.
Survival probabilities were estimated by the Kaplan-Meier
method,23 and the Log-Rank test was used for univariate com-
parison. Median follow up was calculated according to the
reverse Kaplan-Meier method.24 Outcomes were artificially cen-
sored at three years. We used cumulative incidence analysis to
assess NRM, and labeled death from relapse as a competing
event.25,26 The proportional hazards assumption was verified
using graphical methods. Scaled Schoenfeld27 residuals and
graphical checks proposed by Klein and Moeschberger28 were
performed to find evidence of violations. To minimize the effect
of selection bias, we used a landmark analysis at six months
whenever single and tandem ASCT were compared.
To assess the multivariate effect of factors on each end point,
we used the Cox proportional hazards model to estimate hazard
ratios (HR).29 Only complete cases were included in the analysis.
All tests were two-sided, with the type I error rate fixed at
a=0.05. All analyses were performed using the statistical soft-
ware R, v.3.1.0 (R Foundation for Statistical Computing, Vienna,
Austria) and SPSS Statistics 23 (SPSS, IBM Corp, Armonk, NY,
USA).
Results
Incidence and sites
Among the 3744 patients identified in the registry,
14.5% (n=543) had paraskeletal involvement (PS group)
and 3.7% (n=139) extramedullary organ involvement (EM
group), while 81.8% (n=3062) had no EMD (MM group).
Between 2005 and 2014, the EMD incidence per year
increased from 6.5% to 23.7%.
Within the EM group, the involved sites were: kidney
(27.3%, n=38), skin (23.0%, n=32), lymph nodes (17.3%,
n=24), central nervous system (CNS; 10.1%, n=14), lung
and respiratory tract (6.5%, n=9), gastrointestinal tract
(GI) and liver (5.8%, n=8), pleura and heart (5.0%, n=7),
and spleen, ovaries and testes (5.0%, n=7). Most patients
with EMD (93.5%, n=639) presented with one involved
site (PS1 and EM1), 5.7% (n=36) had two sites, 0.7%
(n=5) had three sites, while four and five sites were pres-
ent in 0.1% (n=1) of patients, respectively. Notably, with-
in the PS group, all 19 patients with multiple (≥2) sites
had only additional paraskeletal involvement (PS2), while
further involvement in all 24 EM patients was also
restricted to other organs (EM2). 
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Table 1. Patients’, disease and transplantation characteristics.
Patients without EMD Patients with EMD
Characteristic MM group PS group EM group Total P
N. of patients (%) 3062 (81.8) 543 (14.5) 139 (3.7) 3744
Sex, n. (%)
Female 1279 (41.8) 240 (44.2) 57 (41.0) 1576 (42.1) 0.55
Male 1783 (58.2) 303 (55.8) 82 (59.0) 2168 (57.9)
Age at diagnosis in years
Median 59.8 59.8 59.0 0.59
Range 27.4 to 77.7 26.8 to 76.8 31.8 to 72.8
ISS, n. (%)
I 781 (36.9) 158 (38.6) 29 (30.5) 968 (36.9)
II 759 (35.8) 148 (36.2) 29 (30.5) 936 (35.7) 0.11
III 578 (27.3) 103 (25.2) 37 (38.9) 781 (27.4)
Unknown 944 134 44 1122
Renal function, n. (%)
A 2188 (82.7) 410 (83.2) 85 (65.9) 2683 (82.1) <0.001
B 458 (17.3) 83 (16.8) 44 (34.1) 585 (17.9)
Unknown 416 50 10 476
Karnofsky score, n. (%)
Good 1877 (67.3) 344 (67.7) 81 (62.8) 2302 (67.2)
Poor 914 (32.7) 164 (32.3) 48 (37.2) 1126 (32.8) 0.55
Unknown 271 35 10 316
Status at ASCT, n. (%) 
CR 580 (19.1) 115 (21.5) 16 (11.7) 711 (19.2)
PR 2262 (74.7) 389 (72.6) 109 (79.6) 2760 (74.6) 0.10  
< PR 187 (6.2) 32 (6.0) 12 (8.8) 231 (6.2)
Unknown 33 7 2 42
Type of myeloma, n. (%)
Light chain only 672 (22.1) 122 (22.5) 39 (28.3) 833 (22.4)
Non-secretory 74 (2.4) 29 (5.4) 3 (2.2) 106 (2.9) 0.002
Heavy and light chain 2292 (75.4) 389 (72.0) 96 (69.6) 2777 (74.7)
Unknown 24 3 1 28
Ig-type, n. (%)
G 1648 (70.8) 282 (72.1) 72 (73.5) 2002 (71.1)
A 634 (27.2) 101 (25.8) 22 (22.4) 757 (26.9) 0.51
D/E/M 45 (1.9) 8 (2.0) 4 (4.1) 57 (2.0)
Unknown 735 152 41 928
Light chain type, n. (%)
Kappa 1853 (63.7) 327 (65.1) 73 (55.7) 2253 (63.6) 0.13  
Lambda 1054 (36.3) 175 (34.9) 58 (44.3) 1287 (36.4)
Unknown 155 41 8 204
Years of ASCT, n. (%)
0 3062 (100) 3062 (81.8) <0.001
1 524 (96.5) 115 (82.7) 639 (17.1)
≥ 2 19 (3.5) 24 (17.3) 43 (1.1)
Years of ASCT, n. (%)
< 2009 518 (16.9) 82 (15.1) 25 (18.0) 625 (16.7) 0.001
2009-11 1400 (45.7) 204 (37.6) 62 (44.6) 1666 (44.5)
> 2011 1144 (37.4) 257 (47.3) 52 (37.4) 1453 (38.8)
Time to 1st ASCT in months
Median 6.2 6.2 6.1 0.81
Range 1.1 to 11.9 2.1 to 11.9 3.9 to 11.9
Type of ASCT, n. 
Tandem 249 89 15 353
Single 2813 454 124 3391
EMD: extramedullary disease; MM: patients without extramedullary disease; PS: paraskeletal involvement; EM: extramedullary organ involvement; N.: number; ISS: International
Staging System; ASCT: autologous stem cell transplantation; CR: complete remission; PR: partial remission.
Patients’ and disease characteristics
Median age at diagnosis was 59.8 years in both MM and
PS, and 59.0 years in EM patients (P=0.59). In all groups
there were more males (57.9%) than females (42.1%).
More EM patients (34.1%) had worse renal function (stage
B) in comparison to PS (16.8%) and MM patients (17.3%;
P<0.001). Patients with EM involvement (28.3%) were
more likely to have light chain disease compared to PS
(22.5%) and MM patients (22.1%; P=0.002). More detailed
patients’ characteristics are listed in Table 1. 
Transplantation characteristics and responses
The source of stem cells for all patients was peripheral
blood. A total of 3391 patients underwent up-front single
ASCT and 353 patients up-front tandem ASCT; there was
no difference in time to first ASCT between the two
groups (P=0.81). Complete remission (CR) before the first
ASCT was reported in 21.5% PS, 11.7% EM and 19.1%
MM patients; partial remission (PR) was achieved by
72.6% PS, 79.6% EM and 74.7% MM patients (P=0.1)
(Table 1). After ASCT, complete response was achieved by
41.6% PS, 36.1% EM and 43.9% MM patients, while
54.0% PS, 51.9% EM and 49.8% MM patients showed
partial response (P=0.001).
EMD and survival
Median follow up was 36.3 months (range: 1-118.9
months) after the date of ASCT. In the univariate analysis,
the MM and PS groups showed similar 3-year PFS of
47.9% (95%CI: 45.8-50.1) versus 50.0% (95%CI: 44.6-55.3;
P=0.78) and similar 3-year OS of 80.1% (95%CI: 78.4-81.8)
versus 77.7% (95%CI: 73.3-82.1; P=0.09) (Figure 1A and B).
In contrast, EM patients had a significantly worse 3-year
PFS of 39.9% (95%CI: 30.3-49.5) in comparison to MM
(P=0.001) and PS patients (P=0.007), and a significantly
worse 3-year OS of 58.0% (95%CI: 48.1-67.9) compared
to MM and PS patients (P<0.001, respectively). Within the
EM group, 3-year PFS differed according to involved
organs: kidney (59.5%), skin (20.1%), lymph nodes
(37.6%), CNS (47.9%), lung/respiratory tract (44.4%),
GI/liver (22.5%), and spleen, ovaries and testes (60.0%)
(Table 2).
Comparing the MM group without EMD to those with
EMD, one involved site resulted in a similar 3-year PFS of
49.4% (95%CI: 44.6-54.3; P=0.36) while multiple involved
sites showed a worse PFS of 22.7% (95%CI: 5.2-40.2;
P=0.001) (Figure 2A). Both one and multiple involved sites
showed worse 3-year OS rates of 73.5% (95%CI: 69.2-
77.7; P<0.001) and 71.4% (95%CI: 55.1-87.7; P=0.05) in
comparison to patients without EMD (80.1%) (Figure 2B).
After stratification of EMD groups according to one 
versus multiple involved sites (PS1 vs. PS2, and EM1 vs.
EM2), PS patients showed no significant difference in 3-
year PFS of 50.5% (95%CI: 45.0-55.9%) versus 36.0%
(95%CI: 5.2-66.8%; P=0.71), and OS of 77.2% (95%CI:
72.7-81.7%) versus 91.7% (95%CI: 76.0-100; P=0.27). In
EM patients, this comparison resulted in a significantly
worse 3-year PFS of multiple sites in the univariate analy-
sis: 44.7% (95%CI: 34.1-55.3%) versus 13.9% (95%CI: 0-
35.5%; P=0.03) (Figure 3A). In contrast, 3-year OS was
58.7% (95%CI: 47.9-69.5%) for EM1 versus 57.5%
(95%CI: 34.2-80.8%; P=0.51) (Figure 3B).
Tandem transplantation and survival 
A landmark analysis was used to compare tandem and
single ASCT, considering a total of 3139 patients who were
alive at six months. In patients without EMD, the compar-
ison of tandem versus single ASCT resulted in similar 3-
year PFS, 53.8% (95%CI: 46.7-60.9) versus 51.3% (95%CI:
48.9-53.7; P=0.37), and similar 3-year OS: 84.7% (95%CI:
79.6-89.8) versus 81.6% (95%CI: 79.8-83.4; P=0.26).
Patients with EMD showed a 3-year PFS of 59.0%
(95%CI: 46.3-71.8) after tandem versus 53.0% (95%CI:
47.5-58.6) after single (P=0.43) ASCT, while 3-year OS was
77.0% (95%CI: 66.1-87.9) versus 76.9% (95%CI: 72.4-81.4;
P=0.91). 
Within each EMD group, PS patients showed a similar 3-
year PFS of 59.4% (95%CI: 45.3-73.6) after tandem 
versus 54.3% (95%CI: 48.0-60.5; P=0.44) after single ASCT
and similar 3-year OS of 82.6% (95%CI: 72.3-92.8) versus
Autologous SCT for extramedullary myeloma
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Figure 1. Progression-free survival (A) and overall survival (B) with numbers at risk of myeloma patients following up-front autologous stem cell transplantation
according to presence of involvement. MM: no extramedullary disease; PS: paraskeletal involvement; EM:  extramedullary organ involvement; N: number.
80.3% (95%CI: 75.6-85.1; P=0.88). Patients with EM
involvement showed no significant difference in both 3-
year PFS and OS after tandem versus single transplantation:
56.2% (95%CI: 27.2-85.3) versus 48.3% (95%CI: 36.6-60.1;
P=0.98), and 52.0% (95%CI: 20.0-84.0) versus 64.9%
(95%CI: 54.2-75.7; P=0.39). 
Role of other factors on survival and causes of death
All patients in CR before first ASCT showed a signifi-
cantly better 3-year PFS of 59.8% (95%CI: 55.3-64.3) com-
pared to 30.7% (95%CI: 28.2-33.2) in PR and 24.7%
(95%CI: 17.6-31.8; P<0.001) in less than PR. There was
also a significant difference in 3-year OS, with patients in
CR showing 83.6% (95%CI: 80.2-87.0) compared to
78.8% (95%CI: 76.9-80.6) in patients with PR and 27.8%
(95%CI: 20.8-34.9) in patients with less than PR (P<0.001).
Other factors associated with worse PFS in patients with
EMD were: older age (P=0.04), transplantation before 2011
(P=0.01), higher disease stage according to ISS (P=0.01) and
Salmon and Durie (P=0.02), and lower remission status at
transplantation (P<0.001).  Factors associated with worse
OS in EMD patients were: transplantation before 2011
(P=0.02), higher disease stage according to ISS (P=0.002)
and Salmon and Durie (P=0.02), and lower remission status
at transplantation (P<0.001).
Non-relapse mortality at three years occurred in 3.0%
(95%CI: 2.0-4.0) of MM, 3.0% (95%CI: 2.0-5.0) of PS
patients, and 7.0% (95%CI: 2.0-12.0) of EM patients
(P=0.05). Main causes of death were relapse or progression
(86.3%), infection (7.1%), secondary malignancy or post-
transplant lymphoproliferative disorder (3.6%), organ
damage or failure (1.8%), toxicity (0.4%), and unknown in
83 patients. 
Multivariate analyses
A multivariable model was constructed to examine the
effect of EMD on 3-year PFS and OS after adjusting for
possible prognostic factors. All factors and covariates
including corresponding references are listed in Table 3. To
avoid linearly dependent covariates, we merged the dis-
ease group and the new variable of the number of involved
sites into a 5-level variable consisting of patients without
EMD (MM group) and patients with EMD according to
number of involved sites (PS1, PS2, EM1 and EM2). Cox
proportional hazards regression considering independent
factors for worse PFS yielded significant results for EM2
N. Gagelmann et al.
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Figure 2. Progression-free survival (A) and overall survival (B) with numbers at risk of myeloma patients following up-front autologous stem cell transplantation
according to number of involvements: 0, 1 and ≥ 2. N: number.
Table 2. Involved sites in extramedullary organ involvement (EM) group and survival after autologous stem cell transplantation (ASCT). 
Site N. of N. of deaths 3-year PFS 3-year OS 
patients (%) in % (95% CI) in % (95% CI)
Kidney 38 (27.3) 7 59.5 (41.1 to 77.9) 75.3 (59.0 to 91.7)
CNS 14 (10.1) 4 47.9 (18.3 to 77.4) 64.3 (35.5 to 93.1)
Lung / respiratory tract 9 (6.5) 3 44.4 (7.4 to 81.5) 41.7 (0 to 85.1)
GI tract / liver 8 (5.8) 3 22.5 (0 to 58.8) 58.3 (22.0 to 94.7)
Pleura / heart 7 (5.0) 5 NE NE
Spleen / ovaries / testes 7 (5.0) 2 60.0 (17.1 to 100) 60.0 (17.1 to 100)
Skin 32 (23.0) 10 20.1 (3.4 to 36.7) 53.3 (30.5 to 76.0)
Lymph nodes 24 (17.3) 10 37.6 (16.4 to 58.7) 48.2 (25.1 to 71.3)
PFS: progression-free survival; OS: overall survival; N.: number; CI: Confidence Interval; CNS: central nervous system; GI: gastrointestinal; NE: not estimable.
with an HR of 3.40 (95%CI: 1.74-6.61; P<0.001).
Interestingly, there was no difference in PFS in EM1 com-
pared to MM with an HR of 1.03 (95%CI: 0.66-1.62;
P=0.88). Comparison of PFS between PS and MM showed
no difference for PS1, with an HR of 1.02 (95%CI: 0.83-
1.27; P=0.86), and a less clear HR of 2.46 (95%CI: 0.92-
6.62; P=0.07) for PS2. 
In the OS analysis, EM1 and EM2 were associated with
worse outcome, showing HRs of 2.30 (95%CI: 1.43-3.70;
P=0.001) and 3.64 (95%CI: 1.48-8.94; P=0.01). The differ-
ence between patients with one site of PS involvement and
those without EMD was less clear, with an HR of 1.33
(95%CI: 0.98-1.83; P=0.07), while PS2 resulted in a similar
outcome with an HR of 0.74 (95%CI: 0.10-5.32; P=0.77). 
Tandem ASCT showed similar 3-year PFS and OS com-
pared to single ASCT, with HRs of 0.83 (95%CI: 0.66-1.06;
P=0.13) and 0.74 (95%CI: 0.51-1.09; P=0.13). However,
other factors made a significant contribution to an
increased risk of worse outcome (Table 3). For PFS, these
factors were: ISS stage II and III, PR and less than PR at
ASCT. OS was significantly influenced by ISS stage II and
III, male sex, PR and less than PR at ASCT, and the pres-
ence of heavy and light chains.
Discussion
Extramedullary disease in patients with MM is consid-
ered a poor prognostic factor. This EBMT registry study
including 682 EMD patients identified an increase per year
of EMD incidence at diagnosis from 2005 to 2014. We
demonstrated that first-line ASCT resulted in at least simi-
lar 3-year PFS in patients with single sites of EMD com-
pared to patients without EMD. Another finding, even
though this was less clear, was that this translated into
worse 3-year OS in single PS involvement while single sites
of EM were significantly associated with worse outcome,
which worsened still further when multiple sites of organs
were involved. As far as treatment options for EMD at
diagnosis are concerned, we found both first-line tandem
and single ASCT resulted in similar 3-year PFS and OS.
Evidence on the role of EMD at diagnosis after first-line
ASCT is still limited. A retrospective single center study30
of 27 patients concluded that ASCT might overcome poor
prognosis at onset compared to patients without EMD,
while another study showed extramedullary organ
involvement in only 4 patients and that its impact on out-
come could be under-estimated.5 A prospective study31 of
Autologous SCT for extramedullary myeloma
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Table 3. Multivariate analysis.
3-year PFS 3-year OS
Factors – reference Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Group – MM without EMD < 0.001 < 0.001
PS1 1.02 (0.82 to 1.27) 0.86 1.33 (0.98 to 1.83) 0.07
PS2 2.46 (0.92 to 6.62) 0.07 0.74 (0.10 to 5.32) 0.77
EM1 1.03 (0.66 to 1.62) 0.88 2.30 (1.43 to 3.70) 0.001
EM2 3.40 (1.74 to 6.61) < 0.001 3.64 (1.48 to 8.94) 0.01
Sex – male
Female 0.86 (0.74 to 1.01) 0.06 0.71 (0.56 to 0.91) 0.01
Age in years, > 60 0.22 0.45
< 50 0.81 (0.74 to 1.03) 0.08 1.04 (0.73 to 1.48) 0.85
50 to 60 0.95 (0.80 to 1.11) 0.50 1.17 (0.91 to 1.50) 0.21
ISS – I < 0.001 < 0.001
II 1.48 (1.23 to 1.77) < 0.001 1.75 (1.29 to 2.37) < 0.001
III 1.81 (1.46 to 2.24) < 0.001 2.68 (1.92 to 3.74) < 0.001
Renal function – A
B 0.99 (0.79 to 1.24) 0.93 1.25 (0.92 to 1.69) 0.16
Status at ASCT – CR < 0.001 0.02
PR 1.58 (1.26 to 1.97) < 0.001 1.48 (1.05 to 2.08) 0.03
< PR 2.18 (1.54 to 3.10) < 0.001 2.08 (1.22 to 3.54) 0.01
Type of myeloma - light chain 0.10 0.09
Non-secretory 0.77 (0.42 to 1.43) 0.41 1.70 (0.80 to 3.61) 0.17
Heavy and light 1.19 (0.98 to 1.46) 0.08 1.38 (1.01 to 1.88) 0.04
Year of ASCT - > 2011 0.21 0.91
< 2009 1.22 (0.97 to 1.53) 0.09 1.07 (0.75 to 1.53) 0.71
2009 to 2011 1.05 (0.88 to 1.26) 0.61 1.00 (0.76 to 1.33) 0.98
Type of ASCT - single
Tandem 0.83 (0.66 to 1.06) 0.13 0.74 (0.51 to 1.09) 0.13
PFS: progression-free survival; OS: overall survival; CI: Confidence Interval; MM: patients without extramedullary disease; PS: patients with paraskeletal involvement arising from
bone lesions; PS1: patients with paraskeletal involvement having one involved site; PS2: patients with paraskeletal involvement and multiple involved sites; EM1: patients with
extramedullary organ involvement having one involved site; EM2: patients with extramedullary organ involvement and multiple involved sites; ISS: International Staging System;
CR: complete remission; PR: partial remission; ASCT: autologous stem cell transplantation.
patients in relapse with either soft-tissue or bone-related
involvement at a single institution found that bone-related
relapses were associated with better OS. However, treat-
ments before diagnosis of extramedullary relapse signifi-
cantly differed between groups. Since different types of
involvement were reported, this variable was examined
closely.
In our study, especially EM involvement in 139 MM
patients was associated with lower rate of CR before and
after ASCT, a higher frequency of ISS stage III, and worse
renal function. Importantly, the impact of the number of
involved sites on outcome in EMD at diagnosis had not
previously been described. We found 20% of all EMD
patients having multiple sites of involvement, which is in
line with previous reports (16%).13 Notably, the location
of further involvement was only paraskeletal in the PS
group and was also restricted to other organs in the EM
group.32 
The use of radiation therapy might contribute to the dif-
ference in PFS and OS of patients with single sites of EMD
compared to patients without EMD, because it is consid-
ered effective in reducing progression in patients with soli-
tary osseous and extraosseous involvement,33,34 in particu-
lar because reports about the efficacy of novel agents in
these cohorts at diagnosis are very limited. Some results
would suggest an induction bortezomib-based regimen
followed by high-dose melphalan/ASCT for patients with
paraskeletal rather than extramedullary involvement.14,35-37
In a retrospective study38 investigating carfilzomib alone or
in combination as salvage therapy in relapse, presence of
extramedullary involvement resulted in shorter duration of
response compared to absent EMD, suggesting limited
treatment effect. Smaller reports on the possible impact of
immunomodulatory drugs showed partial efficacy regard-
ing response rates in EMD patients.10,39,40 
Retrospective studies highlighted an extremely poor
prognosis for CNS involvement with a median OS of less
than six months.41,42 However, in addition to systemic anti-
MM therapy, CNS irradiation and the use of novel combi-
nation therapies have been shown to improve the duration
of response.42 With regard to these analyses outside trans-
plantation settings, we investigated survival according to
involved sites in EM patients, finding most of the patients
had kidney, skin or lymph node involvement. After up-
front ASCT, best outcomes were found in kidney and CNS
involvement while skin and lymph node involvement
showed worse outcome. Interestingly, our CNS cohort
showed higher rates of OS compared to previous reports,
which might be due to the selection of patients with CNS
involvement at diagnosis, while most reports evaluated
patients at later phases of the disease.41,42
A pooled analysis of prospective studies regarding trans-
plantation strategies suggested the superiority of tandem
ASCT in patients with poor prognostic features at diagno-
sis.4,43 Our landmark analyses of EMD patients who
received either tandem or single ASCT as first-line therapy
found no difference in PFS and OS. However, this analysis
was conducted with the use of retrospective data and is,
therefore, subject to the attendant limitations. Regression
modeling and landmark analyses were performed as a
means of controlling for differences between the patients,
but such adjustment cannot account for all discrepancies in
clinical and diagnostic characteristics between groups. The
increasing incidence of EMD might be caused by a more
frequent use of whole-body MRI or PET-CT in recent
years. However, although recent evidence promotes the
use of more sensitive imaging techniques,44 data are not
routinely documented, and they are still not part of routine
diagnostics and were thus not available in our study.45,46 A
randomized trial is the only way to overcome these chal-
lenges and to assess the definite impact of EMD in newly
diagnosed MM patients after ASCT. 
In conclusion, this EBMT study identified an increase in
incidence per year of EMD in newly diagnosed MM
patients from 2005 to 2014. We revealed that first-line
ASCT in patients with single sites of EMD (PS or EM)
resulted in at least similar 3-year PFS compared to patients
without EMD. Nevertheless, single EM involvement was
associated with worse 3-year OS, which worsened still fur-
ther when multiple sites of organs were involved. 
N. Gagelmann et al.
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Figure 3. Progression-free survival (A) and overall survival (B) with numbers at risk of myeloma patients with extramedullary organ involvement following up-front
autologous stem cell transplantation according to number of involvements: 1 and ≥ 2. EM: patients with extramedullary organ involvement; EM1: patients with one
site of EM; EM2: patients with two or more sites of EM; N: number. 
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